Objective. T h i s s tu dy ' s ai m w as to a s s e ss th e ef f e c t of h i gh l y a c ti v e an ti r e tr ov i r al d r u g s (HAART) on benign lymphoepithelial cysts (BLEC) of the parotid and ranulas.
both groups received the same combination of HAART and were clinically evaluated for the first three months. Patients with ranulas were followed up for an additional three months. A clinical reduction in the size of the lesions was considered to be a positive outcome.
Results. All parotid glands with BLEC resolved within three months. No positive results were observed in ranulas during the first three months. However, some of the ranulas displayed a positive result after the initial three months of HAART.
Conclusion.
In contrast to BLEC, ranulas in HIV-positive patients seem to present a mixed and delayed response to HAART.
Numerous publications report about HIV-related salivary gland disease (HIV-SGD). HIV-related enlargement of the parotid salivary gland, particularly benign lymphoepithelial cysts (BLEC), remains the most reported form of HIV-SGD. [1] [2] [3] [4] [5] [6] Other salivary glands are affected as well 1 .
However, little has been reported about ranulas as being part of HIV-related salivary gland disease, in particular. The prevalence and the exact etiopathogenesis of BLEC in HIV-positive patients are still unclear, as are the reasons for the frequent observation of ranulas in HIVpositive individuals in Southern Africa.
Different modalities of treatment were previously used for BLEC management: repeated fine needle aspiration (FNA), surgery, radiotherapy, and sclerotherapy. 1, 4, [6] [7] [8] [9] All of these modalities were forms of local and symptomatic treatment. They neither addressed the overall and systemic context of the HIV infection, nor stopped the progression of HIV disease. The advent of highly active antiretroviral therapy (HAART) dramatically changed the way BLEC was managed. Not only did HAART improve the overall quality of life of HIV-infected patients, but HAART 3 indirectly reduced parotid gland swelling. [10] [11] [12] The effect of HAART on parotid gland swelling represents a great achievement regarding cosmetic and HIV-related stigma for patients. HAART has also reduced the need for surgery as a symptomatic treatment of BLEC.
A B Fig.1 . MRI imaging (axial view) of multiple lymphoid infiltrations with bilateral ranulas and HIV-related parotid cysts (1A), and bilateral plunging ranulas (1B).
Currently, the generally accepted standard mode of treatment for ranulas is surgical removal of the offending ipsilateral salivary gland either with or without the attached cystic lesion. [13] [14] [15] However, this radical surgical approach might face limitations in the current clinical presentations of some cases of ranulas in HIV-positive patients. Current cases seem to include more cases of plunging and bilateral ranulas (Fig. 1 ). More importantly, there are reported cases of BLEC co-existing with ranulas in the same subject and in multiple sites (Fig. 1A) . This c l i n i c a l p r e s e n t a t i o n o f b o t h p a t h o l o g i e s i s o f g r e a t e t i o l o g i c a l i m p o r t a n c e a n d p r e s e n t s therapeutic implications in the context of HIV-SGD. The quest for a less invasive modality of treatment for ranulas in HIV-positive patients might, therefore, become a greater challenge. To date, there is no evidence-based proof of treatment for ranulas with HAART. 12 The welldocumented benefit of HAART for BLEC in HIV-positive patients has led these authors to hypothesize that the very same drugs may positively affect ranulas in the context of HIV-SGD. A comparative approach has not been performed before.
The aim of this study is, therefore, to assess how ranulas in HIV-positive patients respond to HAART, and compare the results with those of BLEC in parotid salivary glands in the context of HIV-SGD. Furthermore, a secondary objective is to define the time-frame within which to assess the effectiveness of the therapy in both groups.
PATIENTS AND METHODS
This was a clinical study with both retrospective and prospective components. It involved both pediatric and adult HIV-positive patients who presented with either an enlargement of the parotid glands or a ranula. In both components of the study, every patient acted as his/her own control.
This reduced the effect of other confounding factors such as age, gender, CD 4 + cell count, and blood viral load.
Retrospective study
This retrospective study was based on an audit of charts of 10 HIV-positive patients who presented with an enlarged parotid gland.
The criteria for selection were as follows:
· Patients diagnosed as HIV positive. An HIV-1 antigen (p24) / antibody combination assay was used to establish each patient's HIV status.
· Patients not on HAART at the time of the first consultation.
5
The diagnosis of a lymphoepithelial cyst of the parotid was made on clinical grounds and supported by computed tomography (CT). A fine needle aspiration was also performed.
1,2
Clinical monitoring was performed over a three month period by means of comparative clinical photographs and/or CT scan imaging. Complete or partial reduction in parotid gland swellings was considered to be a positive result.
Prospective study
The prospective component consisted of 14 HIV-positive patients who qualified for the study.
The criteria for patient selection were as follows:
· Patients presenting with a simple or plunging ranula.
· Patients tested for HIV infection if they were unaware of their HIV status.
· Patients not on HAART at the time of consultation.
The diagnosis of ranulas was based on clinical exam. However, CT scan and/or MRI scan imaging were requested in cases of plunging ranulas. Comparative clinical photographs were again used for monitoring purposes at the start of HAART and for a subsequent period of more than three months. Patients who agreed to participate in the study were requested to remain on HAART until three months prior to performing any surgical treatment. Due to the unstable and cystic nature of ranulas, it was not practical to express measurements in centimeters. The effect of HAART on ranulas was assessed clinically by monitoring any reduction in the size of the ranula. As above, a complete or partial size reduction of the ranula was considered to be a positive result.
The assessment included the first three months following the initiation of HAART, as well as a subsequent follow-up period of six months. The three month period provided an element of 6 comparison between the response of BLEC and that of ranulas. The three months also provided a time-frame to initiate further investigations, especially in the case of BLEC.
Antiretroviral drugs
The national antiretroviral treatment guidelines for South African's public health institutions recommend the following regimen: two nucleoside analog reverse transcriptase inhibitors 
RESULTS

I n T a b l e 1 , t h e s o c i o -e p i d e m i o l o g i c d a t a a n d c l i n i c a l r e s u l t s f o r t h e B L E C p a t i e n t s a r e
summarized. In this retrospective study group, all ten patients with BLEC displayed a positive result. The parotid gland swelling was completely reduced to a fraction of their initial size in nine of the ten patients. Fig. 2 (A and B) represents the initial and final clinical status of the enlarged parotid gland in one of the adult HIV-positive patients on HAART. In the prospective study group (Table 2) , all of the 14 selected cases of ranulas displayed a negative result after the first three month period. Neither a clinical reduction in size, nor a modification in radiological imaging of the cystic lesions was observed. There were no differences between simple and plunging ranulas (Figs. 3A and 3B) or between adults and pediatric patients. However, in the subsequent follow-up after the first three month term, ranulas displayed mixed results. Among patients that could not immediately undergo an operation, three 
DISCUSSION
Enlargement of the parotid salivary glands, secondary to benign lymphoepithelial cysts, is the most described form of HIV-SGD. Not only is it a lesion frequently associated with HIV infection, but it is also a presumptive sign of a possible underlying HIV infection in both pediatric and adult patients. The prevalence of ranulas in HIV-positive patients is not well defined. In the specific context of the Southern Africa region, where the prevalence of HIV infection is recognized to be particularly high, the association between HIV infection and oral mucoceles or ranulas is more frequently observed. 12, 17 In the con tex t of HIV-SGD, oral mucoceles and ranulas could, therefore, also be considered an oral lesion frequently associated with HIV.
It is well documented that HAART has a beneficial effect on BLEC in HIV-positive patients.
11,12
Currently there is no need for aggressive treatment such as surgery or radiotherapy to treat this disease. However, the exact mechanism of HAART's action on BLEC remains to be elucidated.
Two main theories have been postulated as to the exact etiopathogenesis of BLEC. Some writers have advocated for an HIV-related reactive lymphoproliferation of glandular epithelium trapped 10 in normal intraparotid lymph nodes. Others researchers have advocated for an obstructive theory that assumes that ductal obstruction by lymphoid proliferation might lead to ductal dilatation that mimics a true cyst. 1, 3, 4, [18] [19] [20] [21] Based on the latter theory, it is possible to elaborate on two possible mechanisms for HAART's action on BLEC. It is reported, on one hand, that HAART decreases the diffuse infiltrative lymphocytosis syndrome (DILS). 22 It is also suggested that DILS is an antigen-driven response, possibly by a viral antigen, and the primary treatment for it is HAART. 22 On the other hand, HAART is credited with an increase in the CD4 + cell count as well as a decrease in the blood viral load. 23 The two actions combined might correlate with the obstructive physiopathogenesis theory, whereas the diminution of DILS due to HAART might The results observed in the prospective component of this study suggest, with great caution, that HAART does not equally influence the course of ranulas in HIV-infected patients. One should be patient and first implement HAART before contemplating a more aggressive approach.
